Nighthawk remains poised for growth despite a recent announcement that it is closing some offices and cutting jobs, according to a financial analyst who follows the company.
Nighthawk remains poised for growth despite a recent announcement that it is closing some offices and cutting jobs, according to a financial analyst who follows the company.
On June 11 Nighthawk announced in its 8-K filing to the Securities and Exchange Commission its plan to reduce operating costs by closing offices in San Francisco and Austin, TX, and a portion of its facility in Coeur d’Alene, ID. The company will lay off 35 employees. Nighthawk says it will incur restructuring costs of approximately $1.1 million, with $600,000 in lease disposal charges, $200,000 in asset write-off charges, and $300,000 in employee severance costs.
Before the June 11 announcement Nighthawk released its commitment to radiologists, setting limits on what it will do to obtain new contracts in hospital settings. That statement was taken by some to mean the company was poised for growth.
Nighthawk did not reply to requests for comment about the layoffs and office closings. But financial analyst Sean Wieland, a managing director and a senior research analyst at Piper Jaffray, said the announcement to close offices and cut jobs was just bad timing.
“I think they’re focusing some of their resources,” he said. “Just like a doctor who identifies cancer in a patient and has to cut some things out, that’s what it looks like they’re doing.”
Nighthawk’s stock has trended down recently. At close of business on June 25 it was trading at $2.63 compared with June 25, 2009, when it traded at $3.76. Still, Wieland recently upgraded his assessment of the stock from sell to neutral. Other analysts recommend holding the stock as well. Two months ago, four analysts had Nighthawk stock at hold and one said it was underperforming.
Nighthawk’s stock may improve because the company is refocusing its business, and a private equity firm just bought their closest competitor, Virtual Radiologic. “If you apply those kinds of multiples to Nighthawk-refocusing their business and their closest competitor being bought out-it’s hard to see a lot of downside left in the stock now,” Wieland said.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.